Cardinal Health Expands Actinium-225 Production

Got story updates? Submit your updates here. ›

Cardinal Health, a leading healthcare services and products company, has announced the expansion of its Actinium-225 production capacity to meet the growing demand for innovative cancer treatments. Actinium-225 is a critical component in the development of novel targeted alpha therapies, which are showing promise in the fight against various types of cancer.

Why it matters

The expansion of Actinium-225 production capacity by Cardinal Health is a significant development in the field of cancer research and treatment. Targeted alpha therapies using Actinium-225 have the potential to revolutionize cancer care by delivering highly targeted and effective treatments with fewer side effects compared to traditional chemotherapy.

The details

Cardinal Health's new production facility will significantly increase the company's ability to supply Actinium-225, a rare and valuable medical isotope, to researchers and pharmaceutical companies developing novel cancer therapies. This expansion is a response to the growing demand for Actinium-225 as more clinical trials and treatments utilizing this isotope are being explored.

• Cardinal Health announced the expansion on April 1, 2026.

What’s next

The expanded Actinium-225 production facility is expected to be operational by the end of 2026, providing a significant boost to the development and availability of targeted alpha therapies for cancer patients.